Related Experiment Video
Updated: Jan 20, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Tim-3 expression in glioma cells is associated with drug resistance
Ji Zhang1, Zheng Quan Zhu2, Yan Xia Li3
1Department of Neurosurgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Objective:
T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) has been widely recognized as a negative regulator of antitumor immunity. However, the mechanism by which Tim-3 suppresses antitumor treatment in gliomas remains unclear. This study aims to explore whether Tim-3 is expressed and to evaluate its effect in drug-fasted glioma cells.
Subjects And Methods:
U87 and U251 glioma cell lines were tested. Cell proliferation activity, cell viability, and the protein and mRNA levels of Tim-3 were detected using CCK-8, flow cytometry, Western blotting, and reverse transcription-quantitative polymerase chain reaction, respectively. Enhancement of the sensitivity of glioma cells to chemotherapeutic agents was tested after inhibiting Tim-3 expression using Tim-3 small interfering RNAs (siRNA).
Results:
As temozolomide (TMZ) concentration increased, the ratio of apoptotic cells also increased accordingly. However, the level of Tim-3 expression in living cells from the high-dose group was higher than in the low- and middle-dose groups. After interfering with the expression of Tim-3 using siRNA against Tim-3, the killing effect of TMZ rose through an increase in apoptosis.
Conclusions:
The presence of Tim-3 mRNA and protein in glioma cells was detected. Significantly, knocking down Tim-3 expression improved the potential of TMZ treatment.
Insights
T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) is present in glioma cells and hinders temozolomide (TMZ) treatment. Inhibiting Tim-3 enhances TMZ
Area of Science:
- Neuro-oncology
- Immunology
- Molecular Biology
Background:
- T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) negatively regulates antitumor immunity.
- The role of Tim-3 in glioma treatment resistance is not fully understood.
Purpose of the Study:
- To investigate Tim-3 expression in glioma cells.
- To evaluate the impact of Tim-3 on drug resistance in glioma.
- To explore Tim-3's role in temozolomide (TMZ) efficacy.
Main Methods:
- U87 and U251 glioma cell lines were used.
- Cell proliferation, viability, and Tim-3 expression (mRNA and protein) were assessed.
- Tim-3 expression was inhibited using small interfering RNA (siRNA) to test chemosensitivity.
Main Results:
- Tim-3 mRNA and protein were detected in glioma cells.
- Higher Tim-3 expression was observed in living cells with increasing temozolomide (TMZ) concentration.
- Inhibiting Tim-3 with siRNA significantly enhanced TMZ's cytotoxic effect by increasing apoptosis.
Conclusions:
- Tim-3 is expressed in glioma cells and contributes to drug resistance.
- Knocking down Tim-3 expression improves the efficacy of temozolomide (TMZ) treatment in gliomas.
Related Concept Videos
Cell Specific Gene Expression
Cell Specific Gene Expression
Resistivity
Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance

